Guardant Health Inc (GH)
22.88
+0.15
(+0.66%)
USD |
NASDAQ |
Sep 27, 16:00
22.91
+0.03
(+0.13%)
After-Hours: 20:00
Guardant Health Research and Development Expense (Annual): 367.19M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 367.19M |
| December 31, 2022 | 373.81M |
| December 31, 2021 | 263.22M |
| December 31, 2020 | 149.86M |
| Date | Value |
|---|---|
| December 31, 2019 | 86.29M |
| December 31, 2018 | 50.71M |
| December 31, 2017 | 25.56M |
| December 31, 2016 | 10.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
86.29M
Minimum
2019
373.81M
Maximum
2022
248.08M
Average
263.22M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Exact Sciences Corp | 425.88M |
| Illumina Inc | 1.354B |
| Delcath Systems Inc | 17.50M |
| CytoSorbents Corp | 15.73M |
| Progyny Inc | -- |